B-intervention	0	5	Serum
I-intervention	6	12	lipids
O	12	13	,
O	14	26	lipoproteins
O	26	27	,
O	28	31	and
O	32	36	risk
O	37	39	of
O	40	46	breast
O	47	53	cancer
O	53	54	:
O	55	56	a
O	57	63	nested
O	64	68	case
O	68	69	-
O	69	76	control
O	77	82	study
O	83	88	using
O	89	97	multiple
O	98	102	time
O	103	109	points
O	109	110	.

O	111	116	There
O	117	119	is
O	120	126	strong
O	127	135	evidence
O	136	140	that
O	141	147	breast
O	148	154	cancer
O	155	159	risk
O	160	162	is
O	163	173	influenced
O	174	176	by
O	177	190	environmental
O	191	198	factors
O	198	199	.

O	200	205	Blood
O	206	211	lipid
O	212	215	and
O	216	227	lipoprotein
O	228	234	levels
O	235	238	are
O	239	243	also
O	244	254	influenced
O	255	257	by
O	258	271	environmental
O	272	279	factors
O	280	283	and
O	284	287	are
O	288	298	associated
O	299	303	with
O	304	308	some
O	309	315	breast
O	316	322	cancer
O	323	327	risk
O	328	335	factors
O	335	336	.

O	337	339	We
O	340	348	examined
O	349	356	whether
O	357	363	serial
O	364	372	measures
O	373	375	of
O	376	381	serum
O	382	388	lipids
O	389	392	and
O	393	405	lipoproteins
O	406	410	were
O	411	421	associated
O	422	426	with
O	427	433	breast
O	434	440	cancer
O	441	445	risk
O	445	446	.

O	447	449	We
O	450	457	carried
O	458	461	out
O	462	463	a
O	464	470	nested
O	471	475	case
O	475	476	-
O	476	483	control
O	484	489	study
O	490	496	within
O	497	498	a
O	499	509	randomized
O	510	514	long
O	514	515	-
O	515	519	term
O	520	527	dietary
O	528	540	intervention
O	541	546	trial
O	547	551	with
B-total-participants	552	556	4690
B-eligibility	557	562	women
I-eligibility	563	567	with
I-eligibility	568	577	extensive
I-eligibility	578	590	mammographic
I-eligibility	591	598	density
I-eligibility	599	607	followed
I-eligibility	608	611	for
I-eligibility	612	614	an
I-eligibility	615	622	average
I-eligibility	623	625	of
I-eligibility	626	628	10
I-eligibility	629	634	years
I-eligibility	635	638	for
I-eligibility	639	645	breast
I-eligibility	646	652	cancer
I-eligibility	653	662	incidence
O	662	663	.

O	664	666	We
O	667	675	measured
O	676	682	lipids
O	683	685	in
O	686	688	an
O	689	696	average
O	697	699	of
O	700	701	4
O	701	702	.
O	702	703	2
O	704	709	blood
O	710	717	samples
O	718	721	for
B-intervention-participants	722	725	279
O	726	734	invasive
O	735	741	breast
O	742	748	cancer
O	749	753	case
O	754	762	subjects
O	763	766	and
B-control-participants	767	770	558
O	771	778	matched
B-control	779	786	control
I-control	787	795	subjects
O	795	796	.

O	797	799	We
O	800	810	calculated
O	811	822	subaverages
O	823	825	of
O	826	832	lipids
O	833	836	for
O	837	841	each
O	842	849	subject
O	850	855	based
O	856	858	on
O	859	869	menopausal
O	870	876	status
O	877	880	and
O	881	884	use
O	885	887	of
O	888	895	hormone
O	896	907	replacement
O	908	915	therapy
O	916	917	(
O	917	920	HRT
O	920	921	)
O	922	924	at
O	925	930	blood
O	931	941	collection
O	942	945	and
O	946	954	analyzed
O	955	960	their
O	961	972	association
O	973	977	with
O	978	984	breast
O	985	991	cancer
O	992	997	using
O	998	1009	generalized
O	1010	1020	estimating
O	1021	1030	equations
O	1030	1031	.

O	1032	1035	All
O	1036	1047	statistical
O	1048	1053	tests
O	1054	1058	were
O	1059	1062	two
O	1062	1063	-
O	1063	1068	sided
O	1068	1069	.

B-outcome	1070	1074	High
I-outcome	1074	1075	-
I-outcome	1075	1082	density
I-outcome	1083	1094	lipoprotein
I-outcome	1094	1095	-
I-outcome	1095	1106	cholesterol
O	1107	1108	(
O	1108	1111	HDL
O	1111	1112	-
O	1112	1113	C
O	1113	1114	)
O	1115	1116	(
O	1116	1117	P
O	1118	1119	=
O	1120	1121	.
O	1121	1123	05
O	1123	1124	)
O	1125	1128	and
B-outcome	1129	1134	apoA1
O	1135	1136	(
O	1136	1137	P
O	1138	1139	=
O	1140	1141	.
O	1141	1143	02
O	1143	1144	)
O	1145	1151	levels
O	1152	1156	were
O	1157	1167	positively
O	1168	1178	associated
O	1179	1183	with
B-outcome	1184	1190	breast
I-outcome	1191	1197	cancer
I-outcome	1198	1202	risk
O	1203	1204	(
O	1204	1206	75
O	1206	1207	(
O	1207	1209	th
O	1209	1210	)
O	1211	1213	vs
O	1214	1216	25
O	1216	1217	(
O	1217	1219	th
O	1219	1220	)
O	1221	1231	percentile
O	1231	1232	:
O	1233	1236	HDL
O	1236	1237	-
O	1237	1238	C
O	1238	1239	,
O	1240	1242	23
O	1242	1243	%
O	1244	1250	higher
O	1250	1251	;
O	1252	1257	apoA1
O	1257	1258	,
O	1259	1261	28
O	1261	1262	%
O	1263	1269	higher
O	1269	1270	)
O	1271	1274	and
B-outcome	1275	1278	non
I-outcome	1278	1279	-
I-outcome	1279	1282	HDL
I-outcome	1282	1283	-
I-outcome	1283	1284	C
O	1285	1286	(
O	1286	1287	P
O	1288	1289	=
O	1290	1291	.
O	1291	1293	03
O	1293	1294	)
O	1295	1298	and
O	1299	1303	apoB
O	1304	1305	(
O	1305	1306	P
O	1307	1308	=
O	1309	1310	.
O	1310	1312	01
O	1312	1313	)
O	1314	1320	levels
O	1321	1325	were
O	1326	1336	negatively
O	1337	1347	associated
O	1348	1349	(
O	1349	1351	75
O	1351	1352	(
O	1352	1354	th
O	1354	1355	)
O	1356	1358	vs
O	1359	1361	25
O	1361	1362	(
O	1362	1364	th
O	1364	1365	)
O	1366	1376	percentile
O	1376	1377	:
O	1378	1381	non
O	1381	1382	-
O	1382	1385	HDL
O	1385	1386	-
O	1386	1387	C
O	1387	1388	,
O	1389	1391	19
O	1391	1392	%
O	1393	1398	lower
O	1398	1399	;
O	1400	1404	apoB
O	1404	1405	,
O	1406	1408	22
O	1408	1409	%
O	1410	1415	lower
O	1415	1416	)
O	1416	1417	.

O	1418	1423	These
O	1424	1436	associations
O	1437	1441	were
O	1442	1450	observed
O	1451	1455	only
O	1456	1460	when
O	1461	1467	lipids
O	1468	1472	were
O	1473	1481	measured
O	1482	1486	when
O	1487	1490	HRT
O	1491	1494	was
O	1495	1498	not
O	1499	1503	used
O	1503	1504	.

B-outcome	1505	1510	Total
I-outcome	1511	1522	cholesterol
I-outcome	1523	1526	and
I-outcome	1527	1539	triglyceride
I-outcome	1540	1546	levels
O	1547	1551	were
O	1552	1555	not
O	1556	1569	statistically
O	1570	1583	significantly
O	1584	1594	associated
O	1595	1599	with
O	1600	1606	breast
O	1607	1613	cancer
O	1614	1618	risk
O	1618	1619	.

O	1620	1625	These
O	1626	1633	results
O	1634	1645	demonstrate
O	1646	1650	that
O	1651	1656	serum
O	1657	1663	lipids
O	1664	1667	are
O	1668	1678	associated
O	1679	1683	with
O	1684	1690	breast
O	1691	1697	cancer
O	1698	1702	risk
O	1703	1705	in
O	1706	1711	women
O	1712	1716	with
O	1717	1726	extensive
O	1727	1739	mammographic
O	1740	1747	density
O	1747	1748	.

O	1749	1752	The
O	1753	1764	possibility
O	1765	1769	that
O	1770	1783	interventions
O	1784	1787	for
O	1788	1793	heart
O	1794	1801	disease
O	1802	1812	prevention
O	1812	1813	,
O	1814	1819	which
O	1820	1823	aim
O	1824	1826	to
O	1827	1833	reduce
O	1834	1837	non
O	1837	1838	-
O	1838	1841	HDL
O	1841	1842	-
O	1842	1843	C
O	1844	1846	or
O	1847	1852	raise
O	1853	1856	HDL
O	1856	1857	-
O	1857	1858	C
O	1858	1859	,
O	1860	1863	may
O	1864	1868	have
O	1869	1876	effects
O	1877	1879	on
O	1880	1886	breast
O	1887	1893	cancer
O	1894	1898	risk
O	1899	1905	merits
O	1906	1917	examination
O	1917	1918	.
